MicroRNA-133a inhibits cell proliferation, colony formation ability, migration and invasion by targeting matrix metallopeptidase 9 in hepatocellular carcinoma

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3900-3907

  Chen, Xian ^a   Bo, Lianhua ^a   Zhao, Xue ^a   Chen, Qi ^a  

^a NANTONG MEDICAL COLLEGE   (China)

Author keywords

Hepatocellular carcinoma; Matrix metallopeptidase 9; MicroRNA 133a

Indexed keywords

GELATINASE B; MICRORNA; MICRORNA 133A; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN133 MICRORNA, HUMAN;

ARTICLE; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL VIABILITY ASSAY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; PROTEIN EXPRESSION; PROTEIN TARGETING; WESTERN BLOTTING; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DRUG SCREENING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 9; MICRORNAS; RNA INTERFERENCE; RNA, MESSENGER; TRANSFECTION; TUMOR STEM CELL ASSAY;

EID: 84922331033     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3232     Document Type: Article

References (53)

1. Kudo M: Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. Oncology 81 (Suppl 1): 1-10, 2011.
2. Meguro M, Mizuguchi T, Kawamoto M and Hirata K: The molecular pathogenesis and clinical implications of hepatocellular carcinoma. Int J Hepatol 2011: 818672, 2011.
3. Yamazaki K, Masugi Y and Sakamoto M: Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis. Dig Dis 29: 284-288, 2011.
4. Rong M, Chen G and Dang Y: Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer 13: 21, 2013.
5. Zou C, Li Y, Cao Y, Zhang J, Jiang J, Sheng Y, Wang S, Huang A and Tang H: Up-regulated MicroRNA-181a induces carcinogenesis in Hepatitis B virus-related hepatocellular carcinoma by targeting E2F5. BMC Cancer 14: 97, 2014.
6. Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG and Qin CK: Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol 9: 47, 2014.
7. Wang L, Yao J, Shi X, Hu L, Li Z, Song T and Huang C: MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer 13: 448, 2013.
8. Aravalli RN, Steer CJ and Cressman EN: Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063, 2008.
9. Thorgeirsson SS, Lee JS and Grisham JW: Functional genomics of hepatocellular carcinoma. Hepatology 43 (2 Suppl 1): S145-S150, 2006.
10. Villanueva A, Newell P, Chiang DY, Friedman SL and Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27: 55-76, 2007.
11. Roessler S, Budhu A and Wang XW: Deciphering cancer heterogeneity: the biological space. Front Cell Dev Biol 2: 12, 2014.
12. Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S, et al: MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol 87: 5270-5286, 2013.
13. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
14. Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105, 2009.
15. Wu D, Ding J, Wang L, Pan H, Zhou Z, Zhou J and Qu P: microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer. Oncol Lett 5: 829-834, 2013.
16. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233, 2009.
17. Ghildiyal M and Zamore PD: Small silencing RNAs: an expanding universe. Nat Rev Genet 10: 94-108, 2009.
18. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
19. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
20. Takahashi RU, Makiko O and Ochiya T: Role of microRNA in cancer development: biology and clinical applications. Nihon Geka Gakkai Zasshi 113: 197-203, 2012 (In Japanese).
21. Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol 774: 1-20, 2013.
22. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K and Kaneko S: Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49: 1098-1112, 2009.
23. Ventura A and Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell 136: 586-591, 2009.
24. Wu D, Zhou Y, Pan H, Zhou J, Fan J and Qu P: microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer. Oncol Lett 7: 1219-1224, 2014.
25. Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou J: MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol 47: 423-432, 2013.
26. Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama K, Nohata N, et al: The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 48: 827-836, 2012.
27. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
28. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N and Nakagawa M: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102: 883-891, 2010.
29. Ruebel K, Leontovich AA, Stilling GA, Zhang S, Righi A, Jin L and Lloyd RV: MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol 23: 367-375, 2010.
30. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J and Lodish HF: Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 24: 3427-3437, 2010.
31. Chomczynski P and Sacchi N: The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nature Protoc 1: 581-585, 2006.
32. Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, Wang M, Zhang Z and Zhang W: microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep 25: 1721-1729, 2011.
33. Dong DL, Chen C, Huo R, Wang N, Li Z, Tu YJ, Hu JT, Chu X, Huang W and Yang BF: Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension 55: 946-952, 2010.
34. Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin C and Zhang W: microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep 27: 1967-1975, 2012.
35. Rao PK, Kumar RM, Farkhondeh M, Baskerville S and Lodish HF: Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Nat Acad Sci USA 103: 8721-8726, 2006.
36. Bostjancic E, Zidar N, Stajer D and Glavac D: MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 115: 163-169, 2010.
37. Uchida Y, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Kawahara K, Nishiyama K, Seki N and Nakagawa M: MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol 31: 115-123, 2013.
38. Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa M: Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol 30: 434-443, 2012.
39. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
40. Han X, Yan DM, Zhao XF, Matsuura H, Ding WG, Li P, Jiang S, Du BR, Du PG and Zhu X: GHGKHKNK octapeptide (P-5m) inhibits metastasis of HCCLM3 cell lines via regulation of MMP-2 expression in in vitro and in vivo studies. Molecules 17: 1357-1372, 2012.
41. Lou L, Chen YX, Jin L, Li X, Tao X, Zhu J, Chen X, Wu S, Ye W, He J, et al: Enhancement of invasion of hepatocellular carcinoma cells through lysophosphatidic acid receptor. J Int Med Res 41: 55-63, 2013.
42. Sun MH, Han XC, Jia MK, Jiang WD, Wang M, Zhang H, Han G and Jiang Y: Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. W J Gastroenterol 11: 5931-5937, 2005.
43. Verma S, Kesh K, Ganguly N, Jana S and Swarnakar S: Matrix metalloproteinases and gastrointestinal cancers: Impacts of dietary antioxidants. World J Biol Chem 5: 355-376, 2014.
44. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7: 3113-3119, 2001.
45. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S and Mazzarino MC: Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33: 44-50, 2005.
46. Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD and Hart J: Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod Pathol 19: 533-540, 2006.
47. Jang JW, Park ST, Kwon JH, You CR, Choi JY, Jung CK, Bae SH and Yoon SK: Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma. Exp Mol Med 43: 305-312, 2011.
48. Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY and Gao DM: Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1alpha, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res 17: 5463-5472, 2011.
49. Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, Liu Y, Ye S and Ren Z: The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol 19 Suppl 3: S375-S384, 2012.
50. Hong S, Park KK, Magae J, Ando K, Lee TS, Kwon TK, Kwak JY, Kim CH and Chang YC: Ascochlorin inhibits matrix metalloproteinase-9 expression by suppressing activator protein-1-mediated gene expression through the ERK1/2 signaling pathway: inhibitory effects of ascochlorin on the invasion of renal carcinoma cells. J Biol Chem 280: 25202-25209, 2005.
51. Santhekadur PK, Gredler R, Chen D, Siddiq A, Shen XN, Das SK, Emdad L, Fisher PB and Sarkar D: Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9). J Biol Chem 287: 3425-3432, 2012.
52. Jiang YF, Yang ZH and Hu JQ: Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol 6: 61-65, 2000.
53. Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y and Saisho H: Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24: 1058-1062, 1996.